Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Better Imaging Doesn't Always Mean Better Diagnosis, Expert Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Overdiagnosis - the diagnosis of a disease more often than it is actually present - is a major problem stemming from the screening of more people with more advanced tools, asserts a Dartmouth College radiologist.

You may also be interested in...



FDA Imaging Endpoint Guidance Tells Sponsors To Charter "Incidental Findings"

Industry is wary of any mandate to report incidental findings to patients and their doctors, worried that it may be “inappropriately delegating a new responsibility to practice medicine by sponsors.” Firms press the agency to revise draft document.

Annual CT Screening Offers Big Mortality Benefit To Smokers – NCI

Annual screening of current and former heavy smokers with computed tomography can reduce their risk of dying from lung cancer by about 20%, according to a large National Cancer Institute-backed study.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071599

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel